CMs over the next few weeks in vivo 5, 22, 23 . Interestingly, recent comparative microarray data suggest that the maturation of CMs is regulated similarly in mice and humans 24 . On the basis of these findings, we explored the potential of the neonatal heart environment to facilitate maturation of CPCs by injecting mouse and human PSC-derived CPCs into neonatal (postnatal days 3-7) rat hearts 21 . To detect the injected cells in the rat hearts, we used fluorescence-labeled CPCs. We injected FACS-isolated mouse CPCs expressing the Isl1-RFP transgene or unsorted human CPCs expressing high percentages of Isl1. We elected to use rats instead of mice because of their larger heart size and the fact that their heart rate is closer to that of the human heart. To avoid cellular rejection, we used immunosuppressed, athymic animals. We sacrificed the rats at various time points and noted that a relatively small percentage (~1%) of the transplanted cells engrafted 21 . CPCs had a much higher survival and engraftment rate and, within 1 month, in vivo-matured PSC-CMs developed the morphological and functional properties of adult CMs, including T-tubule staining, presence of Ca 2+ transients and sarcomere shortening 21 . Moreover, their gene expression pattern, based on single-cell RNA-sequencing analysis, was similar to that of adult CMs. It is worth noting that PSC-CMs do not mature properly when they are injected into older rat hearts (after postnatal day 14; ref. 21) . This suggests the presence of a critical neonatal window that allows PSC-CM maturation.
Applications of the neonatal rat system for the generation of adult-like mature cardiomyocytes from PSCs
In this protocol, we describe how to mature mouse and human PSC-derived CPCs in neonatal rat hearts 21 (Fig. 1) . Our system can be used to further understand the mechanisms of CM maturation, as well as to study the pathogenesis of several adult cardiac diseases. Furthermore, rats with transplanted matured hiPSC-derived-CMs can be used for the in vivo testing of drug therapies and for personalized medicine. Importantly, based on the same principle, our protocol may also be used for the maturation of other cell types, such as neurons, hepatocytes and skeletal muscle cells derived from hiPSCs. In fact, a recent study used the neonatal brain to mature hiPSC-derived neurons in vivo for modeling Alzheimer's disease 25 . Finally, considering the late onset of numerous diseases such as certain familial cardiomyopathies and Alzheimer's disease, the neonatal system may be used to uncover the characteristics of cells at the point of disease onset, enabling earlier disease diagnosis, prevention and better disease management. Steps A (i-xii)
Steps 9-19
Steps B (i-xii)
In vitro differentiation 
Limitations
The main limitation of our protocol is the low cell engraftment, which is primarily due to the small size of the host heart and our current cell delivery method. However, it is very likely that the use of larger animals such as pigs and a higher number of cell injections will markedly improve cellular engraftment and the yield of matured PSC-CMs, which will also potentially allow the in vivo modeling of human diseases in animal models. In addition, the need to generate a genetically modified reporter PSC line in order to locate the injected cells in the host's heart may make our protocol less suitable for the production of mature cardiomyocytes for clinical applications. Coat three wells of a six-well plate with Geltrex as described in Step 1B(i). Dissociate plated hiPSCs as described in Steps 1A(ii) and 1A(iii). Resuspend 6 × 10 5 cells in 6 ml of Essential 8 medium with 10 µM ROCK inhibitor and split over three 15-ml tubes. Quickly thaw one vial of the CAG-GFP/RFP lentivirus and test three different volumes by adding 2, 5 and 10 µl to determine the optimal transduction efficiency of the virus. Mix well and plate the infected hiPSCs in the wells. Incubate in a 5% CO 2 incubator overnight.
Box 1 | Generation of GFP/RFP-tagged human iPSCs
 crItIcal step Split the remaining virus into 2-µl aliquots and store at −80 °C to avoid freeze-thaw cycles, which will decrease the transduction efficiency of the virus. The virus can be maintained without a substantial change in transduction efficiency for up to 1 year. Use bleach to clean all equipment that has come into contact with the virus.  pause poIntCells can be stored in liquid nitrogen for at least 10 years.
6. To thaw the cells, prepare 4 ml of MEF medium prewarmed to 37 °C in a 15-ml tube. Quickly thaw the frozen cells by moving the cryovial from liquid nitrogen directly to a 37 °C water bath, and before the cells are completely thawed, add 1 ml of the prewarmed MEF medium directly to the cells in the cryovial. Mix well with the rest of the MEF medium in the 15-ml tube. Centrifuge for 3 min at 270g at room temperature. Aspirate the supernatant and resuspend the cells in Essential 8 medium with 10 µM ROCK inhibitor (Y27632) and replate them in a T25 flask coated with Matrigel as in Step 1B(i). REAGENT SETUP 2i medium 1 liter of the medium contains 870 ml of GMEM, 100 ml of FBS, 10 ml of GlutaMAX, 10 ml of NEAA, 10 ml of sodium pyruvate, 3 µl of β-mercaptoethanol, 20 µl of LIF (200 U/ml), 0.3 µM CHIR99021 and 0.1 µM PD0325901. Filter-sterilize it using a 1-liter filter and store it at 4 °C for up to 1 month. Mouse embryonic fibroblast (MEF) medium 500 ml of this medium contains 435 ml of DMEM, 50 ml of FBS, 5 ml of NEAA, 5 ml of sodium pyruvate and 5 ml of GlutaMAX. Filter-sterilize using a 500-ml filter and store it at 4 °C for up to 1 month. Serum-free differentiation (SFD) medium 1 liter of SFD medium contains 715 ml of IMDM, 250 ml of Ham's F12, 5 ml of N2 supplement (0.5% vol/vol), 10 ml of B27 minus vitamin A, 5 ml of 10% (wt/vol) BSA (in PBS), 7.5 ml of GlutaMAX and 7.5 ml of penicillin-streptomycin. Filter-sterilize using a 500-ml filter and store it at 4 °C for up to 1 month.  crItIcal To differentiate mESCs, add ascorbic acid (50 µg/ml) and 3.9 × 10 −3 % (vol/vol) monothioglycerol before use.
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FACS sorting solution, 10×
This solution contains 1% (vol/vol) FBS, 200 mM HEPES and 10 mM EDTA in PBS. Filter-sterilize the solution using a 50-ml filter and store it at 4 °C for up to 2 months. RPMI plus B27 minus insulin medium Mix 500 ml of RPMI 1640 medium with 10 ml of B27 minus insulin and store the solution at 4 °C for up to 2 months. RPMI plus B27 minus vitamin A medium Mix 500 ml of RPMI 1640 medium with 10 ml of B27 minus vitamin A, and store the solution at 4 °C for up to 2 months. gelatin-coated 24-well plates. The cells will attach to the bottom and should be incubated in the 5% CO 2 incubator for 1 month while changing the SFD medium every other day. Cells can then be analyzed as described in Box 2. (viii) To dissociate the EBs and collect single CPCs, first centrifuge them at 145g for 3 min at room temperature and aspirate the supernatant. Add 1 ml of TrypLE and incubate at 37 °C for 3 min. Mix well by pipetting to dissociate the cells.  crItIcal step At this time point, almost all the EBs should express Isl1-RFP; this can be checked under the microscope (Fig. 2a) .
? trouBlesHootInG (ix) Add 4 ml of MEF medium to inactivate the TrypLE and mix well by pipetting. To remove the nondissociated EBs, filter the mix using a 70-µm strainer and centrifuge the filtered cells for 3 min at 270g at room temperature. Aspirate the supernatant and add 1 ml of FACS sorting solution to resuspend. (x) To remove all cell clusters before sorting, filter the cells once more using a 5-ml polystyrene round-bottom tube with a 40-µm cell strainer. Keep the cells on ice until sorting. (xi) Sort Isl1-RFP + cells by FACS (Fig. 2b, supplementary Fig. 1 ) and collect the sorted cells in 1 ml of FBS.  crItIcal step To avoid the polymerization of Geltrex, which will increase the viscosity of the cell sample and will clog the microneedle during cell injection, keep the sample on ice at all times for no more than 4 h.  pause poInt Cells can be kept on ice for up to 4 h. Cell death increases with time spent on ice; thus, this should be minimized.
(B) Generation of human ipsc-derived cardiac progenitor cells in vitro • tIMInG 5-6 d
(i) Generate a constitutively expressing GFP/RFP, hiPSC line (Box 1). Grow hiPSCs on Geltrex-coated T25 flasks using Essential 8 medium in a 5% CO 2 incubator set at 37 °C until they reach 70-80% confluence (this usually occurs after 3-4 d), at which point you should proceed to the next step to start cell differentiation. Grow cells in a 5% CO 2 incubator set at 37 °C throughout the experiment. (ii) Transfer the cover glass with plated CMs to the perfusion chamber just before measurement of Ca 2+ transients and sarcomere shortening.
(iii) Measure whole-cell Ca 2+ transients and sarcomere shortening as described in Step 19A.
(c) sorting of cells (i) Sort cells as single cells using a cell sorter, or pick single cells directly under a microscope (EVOS) and transfer them to a 96-well plate for cDNA preparation as above.  crItIcal step For cell maintenance, retain a further 3-6 × 10 5 hiPSCs and replate them in a T25 flask. (vi) Aspirate the supernatant and resuspend the cells you are differentiating in Essential 8 medium with 10 µM ROCK inhibitor (Y27632) at a concentration of 6 × 10 5 hiPSCs per ml and plate 2.5 ml per well of a six-well plate.  crItIcal step 100% confluence is critical to efficient CM differentiation. Therefore, after adding the cells, tap the plate from all sides and leave it inside the hood at room temperature for ~15 min. This will enable more homogeneous plating of the cells. (vii) To initiate cell differentiation the next day, change the medium to RPMI plus B27 minus insulin and 6 µM CHIR99021 and incubate in the 5% CO 2 incubator for 48 h.  crItIcal step To maintain consistency and increase differentiation efficiency, all incubation times stated in this PROCEDURE should remain unchanged. In addition, the medium should always be added slowly to avoid mechanical stress, which can affect cell differentiation. Use 2.5 ml of medium per well. (viii) Change the medium to RPMI plus B27 minus insulin and incubate in the 5% CO 2 incubator for 24 h.
(ix) Change the medium to RPMI plus B27 minus insulin and 10 µM XAV939, and incubate in the 5% CO 2 incubator for 48 h.  crItIcal step If you wish to continue to grow cells in culture rather than proceed to transplantation, change the medium of the cells to RPMI plus B27 minus insulin and incubate in the 5% CO 2 incubator for a further 48 h. Then change the medium to RPMI plus B27 without vitamin A and incubate in the 5% CO 2 incubator for 48 h. At this stage, most cells will be contracting CMs. Cells can be cultured for 1 month, during which time continue changing the medium to RPMI plus B27 without vitamin A every other day. Cells can then be analyzed as described in Box 2.
? trouBlesHootInG (x) The majority of the cells at this stage should express Isl1. To test the percentage of Isl1 + CPCs, perform immunofluorescence staining and flow cytometry of some of the CPCs (Box 3; Fig. 2c ).  crItIcal step To improve the yield of mature CMs, proceed to CPC injection only if ~>60-70% of CPCs are Isl1 + . Alternatively, fresh cardiomyocytes appearing at days 8-9 may be used, with the caveat that their engraftment and survival will be substantially lower in comparison with those of cardiac progenitor cells. 
2|
To anesthetize the rat pups, wrap them in foil and place them on an ice bed (Fig. 3a) . Pups should be anesthetized on the ice bed within 5-10 min.  crItIcal step Take one rat pup at a time and use only postnatal day 1-7 rats. Direct contact of pups with ice is associated with higher postprocedure mortality; therefore, keep pups covered with aluminum foil.  crItIcal step Hypothermia minimizes blood loss during heart surgery and reduces the pup's heart rate, allowing for better cell engraftment.  crItIcal step The time to reach anesthesia varies and depends greatly on the age and weight of the pups. Usually 5 min is enough for P1 (5-7 g) rat pups; however, for P7 (11-13 g) pups, longer times (up to 10 min) are usually needed. ? trouBlesHootInG
3|
Transfer the pup from the ice bed to the surgical bed. Put the rat pup in a supine position and tape all four limbs for immobilization. To sterilize the skin and prevent infections, wipe the chest with a Betadine swab.  crItIcal step For longer anesthesia during surgery, consider cooling the surgical bed using ice or ice packs.
4|
Use the fine scissors (2.5-mm cutting edge) to make an incision of ~5-6 mm in the skin of the left upper chest wall, between the third and fourth ribs (Fig. 3b) . Gently separate the skin from the underlying muscles using fine forceps. Dissect the muscles of the intercostal space and create an opening of ~4-5 mm using the forceps (Fig. 3b) .
5|
Visualize the left ventricular apex and proceed immediately to cell transplantation (Fig. 3c) .  crItIcal step At this stage, the skin and muscles of the chest wall are thin and the heart can usually be located. Entering the anterior mediastinum will require very gentle manipulations and practice to avoid injuring any of the major blood vessels.  crItIcal step Although a wider skin incision can help to visualize the heart better, it will decrease the survival of the pup. 7| After the cell injection, pinch the edges of the chest wall incision with the forceps for 10 s and then use no more than 5 µl of tissue-adhesive glue to seal it (Fig. 3d) .  crItIcal step Higher amounts of tissue glue can be toxic to the pup or can increase the probability of cannibalization by the mother not recognizing her own pups.
8|
Transfer the pup immediately to a heating pad with the temperature set to 37 °C for 10-15 min and then return to the mother.  crItIcal step Ensure that the pup is fully rewarmed and active before returning it to its mother's cage. In addition, rub the pup with cage bedding before returning to its mother to improve survival.  crItIcal step As prolonged hypothermia increases pup mortality, surgery should be completed within 5-10 min.
? trouBlesHootInG
Isolation of transplanted cardiomyocytes from injected rat heart • tIMInG ~1-1.5 h per heart, 30 d after cell injection 9| Transfer the 1-month-old injected rat to the anesthesia induction chamber and euthanize it by adding isoflurane for 3 min.
10|
Quickly remove the heart and place it in perfusion buffer 27 . Cannulate the heart via the aorta and use a Langendorff system to perfuse the heart with perfusion buffer for 3 min at 35-37 °C at a flow of 10 ml per min. Then perfuse for 15 min using collagenase solution at a flow rate of ~3 ml per min. Within 2 min into this perfusion, add 50 µM CaCl 2 .  crItIcal step Decrease the perfusion flow to 2-3 ml per min during collagenase treatment and then increase to 10 ml per min immediately after.
11|
Localize the area of transplanted cells by the presence of an obvious myocardial scar or by visualization of the heart under a fluorescence stereoscopic microscope (Fig. 4a) . Cut the transplanted area using scissors (Student fine scissors) and transfer it into a small plastic container containing 5 ml of collagenase solution, and cut it into smaller pieces (~20 cuts).
12| Add 45 ml of collagenase solution and mix gently up to ten times using a plastic pipette. Transfer 35 ml of supernatant to a 50-ml tube.
13|
Centrifuge the supernatant at 46g for 1 min at room temperature. Transfer 30 ml of the supernatant to the small plastic container with the rest of the heart pieces from Step 11. Retain the pellet.
14|
Place the container on the rocker at low speed for 1 min at room temperature.
15|
Transfer the mix to a new 50-ml tube and centrifuge at 46g for 1 min at room temperature. 
antIcIpateD results
This protocol describes a method to generate mature, adult-like mouse or human PSC-CMs, using neonatal immunosuppressed rats as live bioincubators. It takes advantage of the environmental cues of a neonatal heart to advance CM development, which is otherwise blocked, during their in vitro growth, at late embryonic stages.
1 month after CPC transplantation, isolated mouse or human PSC-CMs should acquire the morphologic and functional characteristics of adult CMs (Fig. 5) . Those cells can be compared with in vitro-matured CMs. We have not observed any teratomas after the injection of highly enriched CPCs. Importantly, as we have demonstrated, in vivo-matured hiPSCs can recapitulate adult cardiomyopathies and can expedite the modeling of diseases that are otherwise challenging to study in vitro 21 . The resulting human-rat chimeras can potentially be used for in vivo drug testing, bringing us a step closer to personalized medicine.
More examples of typical morphologic results can be found in Figure 1 
